Cocrystal Pharma, Inc.
COCP
Price:
$1.7865
Market Cap:
$18.18M
Cocrystal Pharma, Inc., a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases. It employs structure-based technologies to create antiviral drugs primarily to treat hepatitis C virus (HCV), influenza virus, coronavirus, and norovirus infections. The company develops CC-31244, a HCV non-nucleoside polymerase inhibitor that has completed Phase II a clinical trial to treat HCV infection; and CC-42344, a PB2 inhibitor that is in preclinical development trials for treating influenza infection. It is also involved in identifying and developing non-nucleoside polymerase inhibitors for norovirus infections. Cocr...[Read more]
Industry
Biotechnology
IPO Date
2012-02-22
Stock Exchange
NASDAQ
Ticker
COCP
The ROE as of September 2024 (TTM) for Cocrystal Pharma, Inc. (COCP) is -73.89%
According to Cocrystal Pharma, Inc.’s latest financial reports and current stock price. The company's current ROE is -73.89%. This represents a change of 275.42% compared to the average of -19.68% of the last 4 quarters.
Cocrystal Pharma, Inc. (COCP) Historical ROE (quarterly & annually)
How has COCP ROE performed in the past?
The mean historical ROE of Cocrystal Pharma, Inc. over the last ten years is -56.90%. The current -73.89% ROE has changed 29.88% with respect to the historical average. Over the past ten years (40 quarters), COCP's ROE was at its highest in in the December 2017 quarter at 4.93%. The ROE was at its lowest in in the December 2019 quarter at -186.11%.
Average
-56.90%
Median
-49.03%
Minimum
-187.44%
Maximum
-0.58%
Cocrystal Pharma, Inc. (COCP) ROE by Quarter and Year
Discovering the peaks and valleys of Cocrystal Pharma, Inc. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 12.51%
Maximum Annual ROE = -0.58%
Minimum Annual Increase = -100.46%
Minimum Annual ROE = -187.44%
| Year | ROE | Change |
|---|---|---|
| 2023 | -68.16% | -30.57% |
| 2022 | -98.18% | 436.57% |
| 2021 | -18.30% | -0.51% |
| 2020 | -18.39% | -90.19% |
| 2019 | -187.44% | 155.62% |
| 2018 | -73.33% | 12.51% |
| 2017 | -0.58% | -99.21% |
| 2016 | -73.18% | 144.68% |
| 2015 | -29.91% | 1.91% |
| 2014 | -1.49% | -100.46% |
Cocrystal Pharma, Inc. (COCP) Average ROE
How has COCP ROE performed in the past?
The current ROE of Cocrystal Pharma, Inc. (COCP) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-61.54%
5-year avg
-78.09%
10-year avg
-56.90%
Cocrystal Pharma, Inc. (COCP) ROE vs. Peers
How is COCP’s ROE compared to its peers?
Cocrystal Pharma, Inc.’s ROE is less than ZIVO Bioscience, Inc. (673.84%), greater than RenovoRx, Inc. (-403.38%), greater than Tempest Therapeutics, Inc. (-201.10%), greater than Ikena Oncology, Inc. (-42.81%), less than Catalyst Biosciences, Inc. (1.20%), greater than Moleculin Biotech, Inc. (-100.16%), greater than Pulmatrix, Inc. (-61.78%), greater than Cyclacel Pharmaceuticals, Inc. (-1873.74%), less than Akari Therapeutics, Plc (1.04%), greater than Quoin Pharmaceuticals, Ltd. (-112.11%), greater than Blue Water Vaccines, Inc. (-111.44%), greater than PaxMedica, Inc. Common Stock (-1151.68%), greater than Revelation Biosciences, Inc. (-243.91%), greater than Hillstream BioPharma, Inc. (-47249.59%), greater than Onconova Therapeutics, Inc. (-144.95%), greater than Bio-Path Holdings, Inc. (-2842.40%), greater than Allarity Therapeutics, Inc. (-704.78%), less than Kiromic BioPharma, Inc. (337.72%), greater than Virax Biolabs Group Limited (-115.10%), greater than Biodexa Pharmaceuticals Plc (-141.90%),
| Company | ROE | Market cap |
|---|---|---|
| 673.84% | $47.13M | |
| -403.38% | $23.26M | |
| -201.10% | $37.43M | |
| -42.81% | $80.59M | |
| 1.20% | $19.42M | |
| -100.16% | $7.15M | |
| -61.78% | $8.04M | |
| -1873.74% | $2.00M | |
| 1.04% | $39.55M | |
| -112.11% | $2.29M | |
| -111.44% | $3.41M | |
| -1151.68% | $1.06M | |
| -243.91% | $3.68M | |
| -47249.59% | $4.17M | |
| -144.95% | $20.90M | |
| -2842.40% | $2.48M | |
| -704.78% | $3.11M | |
| 337.72% | $2.47M | |
| -115.10% | $11.26M | |
| -141.90% | $100.36K |
Build a custom stock screener for Cocrystal Pharma, Inc. (COCP) and other stocks
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Cocrystal Pharma, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
Cocrystal Pharma, Inc. (COCP) and other stocks custom spreadsheet templates
The easiest way to analyze a company like Cocrystal Pharma, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
Frequently asked questions❓
What is the ROE?
How can you use the ROE?
What is Cocrystal Pharma, Inc.'s ROE?
How is the ROE calculated for Cocrystal Pharma, Inc. (COCP)?
What is the highest ROE for Cocrystal Pharma, Inc. (COCP)?
What is the 3-year average ROE for Cocrystal Pharma, Inc. (COCP)?
What is the 5-year average ROE for Cocrystal Pharma, Inc. (COCP)?
How does the current ROE for Cocrystal Pharma, Inc. (COCP) compare to its historical average?